We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Healthcare Inv | LSE:HIO | London | Ordinary Share | GB00B94T6Y14 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 14.75 | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMCOS
Collagen Solutions PLC
07 November 2018
7 November 2018
Collagen Solutions plc
("Collagen Solutions" or the "Company")
Investor presentation
Collagen Solutions Plc (AIM: COS), the developer and manufacturer of medical grade collagen-based biomaterials for use in research, diagnostics, medical devices, and regenerative medicine, announces it will hold an investor results presentation on Tuesday, 4 December 2018.
The investor event will take place at The Brand Exchange, 3 Birchin Lane, London EC3V 9BW at 4.30pm for a 4.45pm start. This will be followed by drinks and canapes, and a chance to network.
Jamal Rushdy, CEO, and Hilary Spence, CFO, will summarise the half year results and present the key financial highlights, outlook and future vision and how they plan to deliver on the Company's growth strategy.
If you would like to register to attend the investor briefing or require further information, please contact Walbrook PR on 020 7933 8780 or email collagen@walbrookpr.com.
Collagen Solutions Plc Jamal Rushdy, CEO Via Walbrook Hilary Spence, CFO Cenkos Securities Plc (Nominated Adviser and Broker) Steve Cox (Corporate Finance) Tel: 0207 397 8900 Stephen Keys Walbrook PR Ltd Tel: 020 7933 8780 or collagen@walbrookpr.com Anna Dunphy Mob: 07876 741 001 Helen Cresswell Mob: 07841 917 679
About Collagen Solutions:
Collagen Solutions Plc is a global supplier, developer, and manufacturer of medical grade collagen, tissues, and related medical devices and components for use in regenerative medicine, medical devices and in-vitro diagnostics and research. The Company is also expanding its range of biomaterials-based finished medical devices based on its internal and acquired intellectual property for commercialisation with partners via licensing and distribution arrangements, including ChondroMimetic(R). The Company's products are used in a wide variety of applications including orthopaedics, cardiovascular, dental, plastic surgery, wound healing, neurology and urology.
For more information go to: www.collagensolutions.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
NRADMMGMFVFGRZM
(END) Dow Jones Newswires
November 07, 2018 02:00 ET (07:00 GMT)
1 Year Healthcare Inv Chart |
1 Month Healthcare Inv Chart |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions